Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioXcel Therapeutics's Enterprise Value is €97.04 Mil.
BioXcel Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-49.26 Mil. Therefore, BioXcel Therapeutics's EV-to-FCF for today is -1.97.
The historical rank and industry rank for BioXcel Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:BX20'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.13 Med: -1.26 Max: -0.27
Current: -1.93
During the past 10 years, the highest EV-to-FCF of BioXcel Therapeutics was -0.27. The lowest was -6.13. And the median was -1.26.
FRA:BX20's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs FRA:BX20: -1.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioXcel Therapeutics's PE Ratio (TTM) for today is calculated as:
BioXcel Therapeutics's share price for today is €0.72.
BioXcel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.928.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioXcel Therapeutics EV-to-FCF Related Terms
BioXcel Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BX20 vs IXHL, SCYX, INIS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's EV-to-FCF falls into.
BioXcel Therapeutics's current Enterprise Value is €97.04 Mil.
BioXcel Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (FRA:BX20) has a EV-to-FCF of -1.97 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is BioXcel Therapeutics' EV-to-FCF too high?
BioXcel Therapeutics' current EV-to-FCF is -1.97. Based on the distribution chart, BioXcel Therapeutics ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' EV-to-FCF compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #999999 out of 564 companies for EV-to-FCF. This places BioXcel Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 20.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current EV-to-FCF is -1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (FRA:BX20) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.54, compared to a current price of €0.72 — trading 33.3% above its estimated fair value. The current EV-to-FCF is -1.97. BioXcel Therapeutics' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioXcel Therapeutics (FRA:BX20), the current EV-to-FCF is -1.97 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (FRA:BX20) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of €0.72 is trading 33.3% above its estimated GF Value™ of €0.54.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:BX20:
EV-to-FCF: -1.97
GF Value™: €0.54 vs. price of €0.72 (33.3% above fair value)
No single metric tells the full story. See the FRA:BX20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
19GF Score
Get the complete analysis for FRA:BX20
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BX20 has been successfully added to your 
